FDA authorizes first rapid ‘point-of-care’ test for coronavirus/ WaPo

The FDA granted “emergency use authorization” to Cepheid, a California company that makes a rapid molecular test for the coronavirus. The turnaround time for Cepheid’s product is far shorter than for the tests being used, which are typically sent to centralized labs that may not return results for days…”
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
Scroll to Top